对药物负荷的血流动力学反应减弱可预测肝移植候选者的死亡
回顾性研究对比肝移植候选者与匹配对照接受瑞加诺生负荷核素显像,候选者症状更少且心率增幅更低;随访中ΔHR和ΔDBP与死亡独立相关,高MELD合并低ΔHR者生存更差;作者指出需前瞻性研究验证。
要点
- 肝移植候选者瑞加诺生负荷后症状发生率65% vs 对照86%,P < .001。
- 候选者心率增幅ΔHR 13 bpm(IQR 11-15)vs 对照29 bpm(IQR 27-31),P < .001。
- 多变量分析中ΔHR(HZR .975,95%CI .951-.999,P = .042)与ΔDBP(HZR 1.037,95%CI 1.003-1.071,P = .031)与死亡显著相关。
核心结论
- 肝移植候选者接受瑞加诺生负荷试验时血流动力学反应减弱,表现为ΔHR更低且症状更少;血流动力学反应减弱与死亡显著相关,并在MELD评分之外提供增量预后价值;作者指出需进一步前瞻性研究验证这些发现。
研究设计与样本
- 回顾性研究纳入接受瑞加诺生负荷核素负荷试验的肝移植候选者,其中99mTc-替曲膦单光子发射计算机断层显像(SPECT)N = 224例、82铷正电子发射断层显像N = 36例。
- 对照组按年龄、性别、体重指数、心血管合并症和显像方式匹配,接受临床指征的瑞加诺生负荷试验。
主要发现
- 肝移植候选者出现瑞加诺生相关症状的比例低于对照(65% vs 86%,P < .001)。
- 肝移植候选者心率增幅减弱(ΔHR:13次/分,四分位距[IQR]:11-15 vs 29次/分,IQR:27-31,P < .001)。
- 中位随访2.0 ± 1.5年期间,肝移植候选者中发生78例死亡。
- 多变量分析显示ΔHR(风险比[HZR]:.975,95%置信区间[CI]:.951-.999,P = .042)和舒张压变化(ΔDBP,HZR:1.037,95%CI:1.003-1.071,P = .031)与死亡显著相关,不受MELD评分、年龄、心血管合并症和负荷试验结果影响。
- 高MELD评分(≥15)且低ΔHR(≤10次/分)的肝移植候选者总生存差于低MELD评分(<15)且高ΔHR(>10次/分)者(HZR:5.54,95%CI:3.21-9.53,P < .001)、低MELD评分且低ΔHR者(HZR:6.62,95%CI:3.25-13.49,P < .001)以及高MELD评分且低ΔHR者(HZR:2.91,95%CI:1.50-5.64,P = .002)。
关键数值与推荐
- 症状发生率:肝移植候选者65% vs 对照86%,P < .001。
- 心率增幅ΔHR:肝移植候选者13次/分(IQR 11-15)vs 对照29次/分(IQR 27-31),P < .001。
- ΔHR与死亡的风险比HZR .975(95%CI .951-.999,P = .042);ΔDBP与死亡的风险比HZR 1.037(95%CI 1.003-1.071,P = .031)。
- 高MELD(≥15)且低ΔHR(≤10次/分)者对比低MELD(<15)且高ΔHR(>10次/分)者HZR 5.54(95%CI 3.21-9.53,P < .001);对比低MELD且低ΔHR者HZR 6.62(95%CI 3.25-13.49,P < .001);对比高MELD且低ΔHR者HZR 2.91(95%CI 1.50-5.64,P = .002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步前瞻性研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal method for evaluating coronary artery disease in liver transplant candidates (LTCs) remains controversial. To date no studies have compared the hemodynamic and symptomatic response to vasodilator stress between LTCs and patients without chronic liver disease. METHODS: We conducted a retrospective study of LTCs who underwent regadenoson nuclear stress testing with either 99mTc-tetrofosmin single-photon emission computed tomography (SPECT; N = 224) or 82Rubidium positron emission tomography (N = 36). These patients were compared to controls matched for age, sex, body mass index, cardiovascular comorbidities, and imaging modality who underwent clinically indicated regadenoson stress test. RESULTS: LTCs were less likely to experience symptoms in response to regadenoson than controls (65% vs 86 %, P < .001). Additionally, the increase in heart rate was blunted in LTCs (ΔHR: 13 beats per minute [bpm], interquartile range [IQR]: 11-15 vs 29 bpm, IQR: 27-31, P < .001). During the median follow-up period of 2.0 ± 1.5 years, 78 deaths occurred in LTCs. In the multivariable analysis, ΔHR (hazard ratio [HZR]: .975, 95% confidence interval [CI]: .951-.999, P = .042) and changes in diastolic blood pressure (ΔDBP, HZR: 1.037, 95% CI: 1.003-1.071, P = .031) were significantly associated with mortality regardless of Model for End-stage Liver Disease (MELD) score, age, cardiovascular comorbidities, and stress test results. In addition, LTCs with both high MELD score (≥15) and low ΔHR (≤10 bpm) had worse overall survival than patients with a low MELD score (<15) and high ΔHR (>10 bpm, HZR: 5.54, 95% CI: 3.21-9.53, P < .001), low MELD score and low ΔHR (HZR: 6.62, 95% CI: 3.25-13.49, P < .001), and high MELD score and low ΔHR (HZR: 2.91, 95% CI: 1.50-5.64, P = .002). CONCLUSIONS: In this retrospective cohort analysis, LTCs exhibited a reduced hemodynamic response detected as lower ΔHR as well as fewer symptoms in response to regadenoson during stress testing. Reduced hemodynamic response was significantly associated with mortality and provided incremental prognostic value in addition to MELD score. Further prospective studies are required to validate these findings.
引用
- Csecs I, Sharma A, Khungar V, et al. Blunted hemodynamic response to pharmacological stress is predictive of mortality in liver transplant candidates. J Nucl Cardiol. 2025. PMID: 40769316. doi:10.1016/j.nuclcard.2025.102454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。